There are currently three US FDA-approved PARP inhibitors that are approved for treatment of four histologic types of solid malignancies, including: i) ovarian cancer, ii) epithelial fallopian tube cancer, iii) primary peritoneal cancer, and iv) breast cancer. The gene discussed is PARP1; the disease is ovarian cancer.